Pear Therapeutics Looks For A Buyer As It Struggles To Get Paid For Prescription Apps

Pear Therapeutics, which has three FDA-cleared prescription apps to help treat substance use disorder and insomnia, announced Friday it was “exploring strategic alternatives,” including a sale, merger or licensing of assets, and would no longer hold a fourth quarter earnings call. The move highlights the main challenge facing companies developing software as medicine: getting commercial insurers and government health programs to pay for it.